MVA-5T4
AXP000184.1 · Cancer vaccine
- Platform
- MVA
- Targets
- TPBG
- Originator
- Oxford BioMedica
- Sponsor
- Oxford BioMedica
Names
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Strain
- MVA
- Replication
- non replicating
- Modifications
- human 5T4 (TPBG) cassette inserted into MVA
- Transgenes
- TPBG
- Source
- evidence
Cross-references
- NCI Thesaurus
- C49087
- FDA UNII
- P258UUW1OD
Approvals
No regulatory approval recorded.
Clinical trials (11)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT02390063 | Vaccination in Prostate Cancer (VANCE) | Completed | Phase 1 | 2015-06 | 2018-05-15 | 40 | Prostate Cancer |
| NCT01556841 | The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer | Completed | Phase 2 | 2013-11 | 2019-04-19 | 94 | Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer |
| NCT01569919 | A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma | Unknown | Phase 2 | 2012-12 | 2014-06 | 26 | Malignant; Mesothelioma; Pleural |
| NCT01194960 | TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC) | Terminated | Phase 2 | 2010-08 | 2013-03 | 25 | Hormone Refractory Prostate Cancer |
| NCT00521274 | Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer | Terminated | Phase 2 | 2007-08 | 2008-07 | 11 | Prostatic Neoplasms |
| NCT00397345 | TroVax Renal Immunotherapy Survival Trial | Completed | Phase 3 | 2006-09 | 2009-12 | 733 | Clear Cell Renal Carcinoma |
| NCT00448409 | Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer | Completed | Phase 2 | 2006-05 | 2007-04 | 27 | Prostatic Neoplasms |
| NCT00445523 | Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer | Completed | Phase 2 | 2006-05 | 2008-01 | 28 | Carcinoma, Renal Cell |
| NCT00325507 | Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma | Completed | Phase 2 | 2005-11 | 2008-07 | 25 | Carcinoma, Renal Cell |
| NCT00083941 | A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer | Completed | Phase 2 | 2004-08 | 2008-07 | 25 | Carcinoma, Renal Cell |
| NCT00259844 | Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed | Completed | Phase 2 | 2004-06 | 20 | Colorectal Neoplasms |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38760075 | A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC). | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2024 | cited by trial NCT01556841 |
| PMID 32591433 | Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. | Journal for immunotherapy of cancer | 2020 | cited by trial NCT02390063 |
| PMID 28880972 | Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial. | JAMA oncology | 2017 | name in abstract: MVA-5T4 |
| PMID 23877659 | Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial. | Cancer immunology, immunotherapy : CII | 2013 | cited by trial NCT01194960 |
| PMID 22692758 | Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax). | Cancer immunology, immunotherapy : CII | 2012 | name in title: TroVax |
| PMID 21387109 | MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. | Cancer immunology, immunotherapy : CII | 2011 | name in title: MVA-5T4 |
| PMID 20881001 | Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2010 | cited by trial NCT00397345 |
| PMID 20948436 | Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2010 | name in title: TroVax |
| PMID 19128501 | Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. | Journal of translational medicine | 2009 | cited by trial NCT00083941 |
| PMID 19342962 | Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2009 | name in title: TroVax |
| PMID 19561532 | Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2009 | name in title: TroVax |
| PMID 18060404 | Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. | Cancer immunology, immunotherapy : CII | 2008 | name in title: TroVax |
| PMID 18528296 | Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2008 | name in title: TroVax |
| PMID 18833005 | An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2008 | name in abstract: TroVax |
| PMID 19010868 | Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2008 | cited by trial NCT00325507 |
| PMID 17671134 | Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2007 | name in title: TroVax |
| PMID 16740766 | Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2006 | name in title: TroVax |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 30524880 | A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial. | Oncoimmunology | 2018 | name in title: TroVax |
| PMID 28504837 | Immunotherapy for metastatic renal cell carcinoma. | The Cochrane database of systematic reviews | 2017 | name in abstract: MVA-5T4 |
| PMID 25262701 | Clinical outcomes model in renal cell cancer patients treated with modified vaccinia Ankara plus tumor-associated antigen 5T4. | The International journal of biological markers | 2015 | name in abstract: MVA-5T4 |
| PMID 25483641 | TroVax in colorectal cancer. | Human vaccines & immunotherapeutics | 2014 | name in title: TroVax |
| PMID 23603858 | Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4. | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2013 | name in abstract: MVA-5T4 |
| PMID 23875174 | Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4. | Frontiers in oncology | 2013 | name in title: MVA-5T4 |
| PMID 22149999 | TroVax(®) vaccine therapy for renal cell carcinoma. | Immunotherapy | 2012 | name in title: TroVax |
| PMID 22253556 | Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer. | Clinical Medicine Insights. Oncology | 2012 | name in title: TroVax |
| PMID 22409460 | Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer. | Future oncology (London, England) | 2012 | name in title: MVA-5T4 |
| PMID 22892449 | CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model. | Journal of immunotherapy (Hagerstown, Md. : 1997) | 2012 | name in abstract: MVA-5T4 |
| PMID 21691576 | An update on TroVax for the treatment of progressive castration-resistant prostate cancer. | OncoTargets and therapy | 2011 | name in title: TroVax |
| PMID 20088718 | 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. | Expert opinion on biological therapy | 2010 | name in abstract: TroVax |
| PMID 20975327 | TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development. | Human vaccines | 2010 | name in title: TroVax |
| PMID 19221742 | Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). | Cancer immunology, immunotherapy : CII | 2009 | name in title: TroVax |
| PMID 18004564 | CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells. | Cancer immunology, immunotherapy : CII | 2008 | name in abstract: TroVax |
| PMID 18567615 | Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. | International immunology | 2008 | name in abstract: TroVax |
| PMID 18990081 | Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. | Expert opinion on biological therapy | 2008 | name in abstract: MVA-5T4 |
| PMID 17727334 | 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy. | Expert opinion on biological therapy | 2007 | name in abstract: TroVax |
| PMID 17922073 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2007 | name in abstract: MVA-5T4 |
| PMID 16311730 | Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. | Cancer immunology, immunotherapy : CII | 2006 | name in title: TroVax |
| PMID 16630022 | Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. | Immunology | 2006 | name in abstract: TroVax |
| PMID 16179960 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2005 | name in abstract: MVA-5T4 |
| PMID 14988742 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2004 | name in abstract: MVA-5T4 |
| PMID 15468602 | Technology evaluation: TroVax, Oxford BioMedica. | Current opinion in molecular therapeutics | 2004 | name in title: TroVax |
| PMID 12481437 | Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. | Molecular cancer therapeutics | 2002 | name in abstract: MVA-5T4 |
Notes
TroVax: MVA encoding the oncofetal antigen 5T4 (TPBG); trials in colorectal, renal and prostate cancer, including the phase 3 TRIST study in renal cell carcinoma (NCT00397345) - the phase 3 designation and result were not verified from a primary source in this pass. Also carries the Oxford BioMedica code OXB-301.
How to cite
MVA-5T4 (AXP000184.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000184.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.